Build Your Comparison

Side-by-side financial analysis
ADAG logo
ADAG
MGTX logo
MGTX
KO logo
KO
REGN logo
REGN
PEP logo
PEP
JPM logo
JPM
Try popular comparisons:

Stock Comparison

ADAG vs MGTX vs KO vs REGN vs PEP vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ADAG
Adagene Inc.

Biotechnology

HealthcareNASDAQ • CN
Market Cap$210M
5Y Perf.-85.4%
MGTX
MeiraGTx Holdings plc

Biotechnology

HealthcareNASDAQ • US
Market Cap$888M
5Y Perf.-35.4%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+68.6%
REGN
Regeneron Pharmaceuticals, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$63.60B
5Y Perf.+35.9%
PEP
PepsiCo, Inc.

Beverages - Non-Alcoholic

Consumer DefensiveNASDAQ • US
Market Cap$197.17B
5Y Perf.+11.7%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+117.9%

ADAG vs MGTX vs KO vs REGN vs PEP vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ADAG logoADAG
MGTX logoMGTX
KO logoKO
REGN logoREGN
PEP logoPEP
JPM logoJPM
IndustryBiotechnologyBiotechnologyBeverages - Non-AlcoholicBiotechnologyBeverages - Non-AlcoholicBanks - Diversified
Market Cap$210M$888M$355.61B$63.60B$197.17B$896.00B
Revenue (TTM)$103K$80M$49.28B$14.92B$93.92B$280.33B
Net Income (TTM)$-55M$-121M$13.70B$4.42B$8.24B$57.05B
Gross Margin-10.9%91.6%61.7%84.5%54.1%60.0%
Operating Margin-589.5%-131.9%29.3%24.3%12.2%25.9%
Forward P/E25.3x13.2x16.7x14.4x
Total Debt$18M$89M$45.49B$2.71B$49.90B$942.38B
Cash & Equiv.$85M$66M$10.27B$3.12B$9.16B$343.34B

ADAG vs MGTX vs KO vs REGN vs PEP vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ADAG
MGTX
KO
REGN
PEP
JPM
StockFeb 21Jun 26Return
Adagene Inc. (ADAG)10014.6-85.4%
MeiraGTx Holdings p… (MGTX)10064.6-35.4%
The Coca-Cola Compa… (KO)100168.6+68.6%
Regeneron Pharmaceu… (REGN)100135.9+35.9%
PepsiCo, Inc. (PEP)100111.7+11.7%
JPMorgan Chase & Co. (JPM)100217.9+117.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: ADAG vs MGTX vs KO vs REGN vs PEP vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: REGN leads in 2 of 7 categories (6-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Adagene Inc. is the stronger pick specifically for recent price momentum and sentiment. MGTX, KO, PEP, and JPM also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇REGN emerged as the overall leader. Track its performance:
ADAG
Adagene Inc.
The Momentum Pick

ADAG is the #2 pick in this set and the best alternative if momentum is your priority.

  • +82.1% vs PEP's +13.4%
Best for: momentum
MGTX
MeiraGTx Holdings plc
The Growth Play

MGTX ranks third and is worth considering specifically for growth exposure.

  • Rev growth 144.6%, EPS growth 33.0%, 3Y rev CAGR 72.3%
  • 144.6% revenue growth vs ADAG's -99.4%
Best for: growth exposure
KO
The Coca-Cola Company
The Niche Pick

KO is the clearest fit if your priority is efficiency.

  • 13.1% ROA vs ADAG's -83.3%
Best for: efficiency
REGN
Regeneron Pharmaceuticals, Inc.
The Defensive Pick

REGN has the current edge in this matchup, primarily because of its strength in sleep-well-at-night and defensive.

  • Lower volatility, beta 0.51, Low D/E 8.7%, current ratio 4.13x
  • Beta 0.51, yield 0.6%, current ratio 4.13x
  • 29.6% margin vs ADAG's -537.2%
  • Beta 0.51 vs MGTX's 1.94
Best for: sleep-well-at-night and defensive
PEP
PepsiCo, Inc.
The Income Pick

PEP is the clearest fit if your priority is income & stability.

  • Dividend streak 54 yrs, beta -0.11, yield 3.9%
  • 3.9% yield, 54-year raise streak, vs KO's 2.5%, (2 stocks pay no dividend)
Best for: income & stability
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is long-term compounding and valuation efficiency.

  • 465.8% 10Y total return vs KO's 121.1%
  • PEG 0.81 vs PEP's 5.11
  • Lower P/E (14.4x vs 16.7x), PEG 0.81 vs 5.11
Best for: long-term compounding and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthMGTX logoMGTX144.6% revenue growth vs ADAG's -99.4%
ValueJPM logoJPMLower P/E (14.4x vs 16.7x), PEG 0.81 vs 5.11
Quality / MarginsREGN logoREGN29.6% margin vs ADAG's -537.2%
Stability / SafetyREGN logoREGNBeta 0.51 vs MGTX's 1.94
DividendsPEP logoPEP3.9% yield, 54-year raise streak, vs KO's 2.5%, (2 stocks pay no dividend)
Momentum (1Y)ADAG logoADAG+82.1% vs PEP's +13.4%
Efficiency (ROA)KO logoKO13.1% ROA vs ADAG's -83.3%

ADAG vs MGTX vs KO vs REGN vs PEP vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
ADAGAdagene Inc.
FY 2020
Service
63.9%$398,883
License
36.1%$225,000
MGTXMeiraGTx Holdings plc
FY 2025
License
92.1%$75M
Related Party Service Revenue
7.9%$6M
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B
REGNRegeneron Pharmaceuticals, Inc.
FY 2025
Collaboration Revenue
51.1%$7.3B
Product
44.0%$6.3B
Product and Service, Other
4.9%$703M
PEPPepsiCo, Inc.

Segment breakdown not available.

JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

ADAG vs MGTX vs KO vs REGN vs PEP vs JPM — Financial Metrics

Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGJPM

Income & Cash Flow (Last 12 Months)

REGN leads this category, winning 2 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 2716299.8x ADAG's $103,204. REGN is the more profitable business, keeping 29.6% of every revenue dollar as net income compared to ADAG's -537.2%. On growth, REGN holds the edge at +19.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricADAG logoADAGAdagene Inc.MGTX logoMGTXMeiraGTx Holdings…KO logoKOThe Coca-Cola Com…REGN logoREGNRegeneron Pharmac…PEP logoPEPPepsiCo, Inc.JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$103,204$80M$49.3B$14.9B$93.9B$280.3B
EBITDAEarnings before interest/tax-$59M-$92M$15.5B$4.2B$14.3B$81.4B
Net IncomeAfter-tax profit-$55M-$121M$13.7B$4.4B$8.2B$57.0B
Free Cash FlowCash after capex-$48M-$2M$12.6B$4.2B$7.7B$100.9B
Gross MarginGross profit ÷ Revenue-10.9%+91.6%+61.7%+84.5%+54.1%+60.0%
Operating MarginEBIT ÷ Revenue-589.5%-131.9%+29.3%+24.3%+12.2%+25.9%
Net MarginNet income ÷ Revenue-537.2%-151.1%+27.8%+29.6%+8.8%+20.4%
FCF MarginFCF ÷ Revenue-461.1%-2.9%+25.5%+27.9%+8.2%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year-84.8%+12.1%+19.0%+5.6%
EPS Growth (YoY)Latest quarter vs prior year-50.0%-11.8%+18.2%-7.2%+66.7%+16.0%
REGN leads this category, winning 2 of 6 comparable metrics.

Valuation Metrics

REGN leads this category, winning 3 of 7 comparable metrics.

At 14.8x trailing earnings, REGN trades at a 46% valuation discount to KO's 27.2x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs PEP's 7.37x — a lower PEG means you pay less per unit of expected earnings growth.

MetricADAG logoADAGAdagene Inc.MGTX logoMGTXMeiraGTx Holdings…KO logoKOThe Coca-Cola Com…REGN logoREGNRegeneron Pharmac…PEP logoPEPPepsiCo, Inc.JPM logoJPMJPMorgan Chase & …
Market CapShares × price$210M$888M$355.6B$63.6B$197.2B$896.0B
Enterprise ValueMkt cap + debt − cash$144M$911M$390.8B$63.2B$237.9B$1.50T
Trailing P/EPrice ÷ TTM EPS-3.76x-6.75x27.18x14.76x24.05x16.00x
Forward P/EPrice ÷ next-FY EPS est.25.27x13.18x16.68x14.40x
PEG RatioP/E ÷ EPS growth rate2.43x2.33x7.37x0.90x
EV / EBITDAEnterprise value multiple26.39x15.33x16.63x18.36x
Price / SalesMarket cap ÷ Revenue2037.00x10.91x7.42x4.43x2.10x3.20x
Price / BookPrice ÷ Book value/share2.55x10.40x2.13x9.63x2.47x
Price / FCFMarket cap ÷ FCF67.15x15.59x25.70x8.88x
REGN leads this category, winning 3 of 7 comparable metrics.

Profitability & Efficiency

KO leads this category, winning 5 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-4 for MGTX. REGN carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs ADAG's 1/9, reflecting strong financial health.

MetricADAG logoADAGAdagene Inc.MGTX logoMGTXMeiraGTx Holdings…KO logoKOThe Coca-Cola Com…REGN logoREGNRegeneron Pharmac…PEP logoPEPPepsiCo, Inc.JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-146.2%-3.7%+41.1%+14.3%+40.1%+15.9%
ROA (TTM)Return on assets-83.3%-55.0%+13.1%+11.1%+7.7%+1.3%
ROICReturn on invested capital-2.4%+15.8%+8.9%+14.9%+4.5%
ROCEReturn on capital employed-53.1%-64.1%+17.3%+10.2%+16.1%+8.9%
Piotroski ScoreFundamental quality 0–9147555
Debt / EquityFinancial leverage0.37x1.33x0.09x2.43x2.60x
Net DebtTotal debt minus cash-$67M$23M$35.2B-$412M$40.7B$599.0B
Cash & Equiv.Liquid assets$85M$66M$10.3B$3.1B$9.2B$343.3B
Total DebtShort + long-term debt$18M$89M$45.5B$2.7B$49.9B$942.4B
Interest CoverageEBIT ÷ Interest expense-46.92x-8.82x10.70x108.44x10.34x0.74x
KO leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ADAG leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $2,627 for ADAG. Over the past 12 months, ADAG leads with a +82.1% total return vs PEP's +13.4%. The 3-year compound annual growth rate (CAGR) favors ADAG at 42.3% vs REGN's -6.4% — a key indicator of consistent wealth creation.

MetricADAG logoADAGAdagene Inc.MGTX logoMGTXMeiraGTx Holdings…KO logoKOThe Coca-Cola Com…REGN logoREGNRegeneron Pharmac…PEP logoPEPPepsiCo, Inc.JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date+94.0%+22.8%+20.3%-20.9%+3.5%-0.5%
1-Year ReturnPast 12 months+82.1%+45.5%+17.2%+18.0%+13.4%+21.8%
3-Year ReturnCumulative with dividends+187.9%+27.4%+47.0%-18.1%-11.7%+138.2%
5-Year ReturnCumulative with dividends-73.7%-36.8%+65.6%+16.8%+14.3%+118.2%
10-Year ReturnCumulative with dividends-88.1%-36.1%+121.1%+68.2%+82.3%+465.8%
CAGR (3Y)Annualised 3-year return+42.3%+8.4%+13.7%-6.4%-4.1%+33.6%
ADAG leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than MGTX's 1.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs REGN's 74.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricADAG logoADAGAdagene Inc.MGTX logoMGTXMeiraGTx Holdings…KO logoKOThe Coca-Cola Com…REGN logoREGNRegeneron Pharmac…PEP logoPEPPepsiCo, Inc.JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5000.73x1.94x-0.20x0.51x-0.11x0.94x
52-Week HighHighest price in past year$4.75$11.85$84.04$821.11$171.48$337.25
52-Week LowLowest price in past year$1.30$6.07$65.35$503.25$127.60$262.71
% of 52W HighCurrent price vs 52-week peak+75.2%+80.9%+98.3%+74.6%+84.1%+95.1%
RSI (14)Momentum oscillator 0–10049.951.660.637.541.659.1
Avg Volume (50D)Average daily shares traded214K800K12.7M868K6.0M7.0M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — KO and PEP each lead in 1 of 2 comparable metrics.

Analyst consensus: ADAG as "Buy", MGTX as "Buy", KO as "Buy", REGN as "Buy", PEP as "Hold", JPM as "Buy". Consensus price targets imply 160.7% upside for MGTX (target: $25) vs 4.2% for KO (target: $86). For income investors, PEP offers the higher dividend yield at 3.86% vs REGN's 0.56%.

MetricADAG logoADAGAdagene Inc.MGTX logoMGTXMeiraGTx Holdings…KO logoKOThe Coca-Cola Com…REGN logoREGNRegeneron Pharmac…PEP logoPEPPepsiCo, Inc.JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyHoldBuy
Price TargetConsensus 12-month target$5.00$25.00$86.13$836.00$167.88$339.75
# AnalystsCovering analysts5648484561
Dividend YieldAnnual dividend ÷ price+2.5%+0.6%+3.9%+1.9%
Dividend StreakConsecutive years of raises5615415
Dividend / ShareAnnual DPS$2.04$3.41$5.57$5.95
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.2%+6.2%+0.5%+3.9%
Evenly matched — KO and PEP each lead in 1 of 2 comparable metrics.
Key Takeaway

REGN leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). KO leads in 2 (Profitability & Efficiency, Risk & Volatility). 1 tied.

Best OverallThe Coca-Cola Company (KO)Leads 2 of 6 categories
Loading custom metrics...

ADAG vs MGTX vs KO vs REGN vs PEP vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ADAG or MGTX or KO or REGN or PEP or JPM a better buy right now?

For growth investors, MeiraGTx Holdings plc (MGTX) is the stronger pick with 144.

6% revenue growth year-over-year, versus -99. 4% for Adagene Inc. (ADAG). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 14. 8x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Adagene Inc. (ADAG) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ADAG or MGTX or KO or REGN or PEP or JPM?

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 14. 8x versus The Coca-Cola Company at 27. 2x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 13. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus PepsiCo, Inc. 's 5. 11x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — ADAG or MGTX or KO or REGN or PEP or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -73. 7% for Adagene Inc. (ADAG). Over 10 years, the gap is even starker: JPM returned +465. 8% versus ADAG's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ADAG or MGTX or KO or REGN or PEP or JPM?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus MeiraGTx Holdings plc's 1. 94β — meaning MGTX is approximately -1071% more volatile than KO relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ADAG or MGTX or KO or REGN or PEP or JPM?

By revenue growth (latest reported year), MeiraGTx Holdings plc (MGTX) is pulling ahead at 144.

6% versus -99. 4% for Adagene Inc. (ADAG). On earnings-per-share growth, the picture is similar: MeiraGTx Holdings plc grew EPS 33. 0% year-over-year, compared to -75. 9% for Adagene Inc.. Over a 3-year CAGR, MGTX leads at 72. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ADAG or MGTX or KO or REGN or PEP or JPM?

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -323. 9% for Adagene Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -348. 4% for ADAG. At the gross margin level — before operating expenses — MGTX leads at 94. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ADAG or MGTX or KO or REGN or PEP or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus PepsiCo, Inc. 's 5. 11x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 13. 2x forward P/E versus 25. 3x for The Coca-Cola Company — 12. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MGTX: 160. 7% to $25. 00.

08

Which pays a better dividend — ADAG or MGTX or KO or REGN or PEP or JPM?

In this comparison, PEP (3.

9% yield), KO (2. 5% yield), JPM (1. 9% yield), REGN (0. 6% yield) pay a dividend. ADAG, MGTX do not pay a meaningful dividend and should not be held primarily for income.

09

Is ADAG or MGTX or KO or REGN or PEP or JPM better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). MeiraGTx Holdings plc (MGTX) carries a higher beta of 1. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, MGTX: -36. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ADAG and MGTX and KO and REGN and PEP and JPM?

These companies operate in different sectors (ADAG (Healthcare) and MGTX (Healthcare) and KO (Consumer Defensive) and REGN (Healthcare) and PEP (Consumer Defensive) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ADAG is a small-cap quality compounder stock; MGTX is a small-cap high-growth stock; KO is a large-cap quality compounder stock; REGN is a mid-cap deep-value stock; PEP is a mid-cap income-oriented stock; JPM is a large-cap deep-value stock. KO, REGN, PEP, JPM pay a dividend while ADAG, MGTX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.